Relistor (methylnaltrexone bromide for SC injection, from Progenics and Wyeth) has been approved for the treatment of opioid-induced constipation (OIC) in palliative care patients with advanced illness, when response to laxative therapy has been insufficient. In clinical studies, Relistor significantly decreased the constipating effects of opioids without interfering with pain relief.

Relistor, a peripherally acting mu-opioid receptor antagonist, is expected to be available in June 2008.

For more information call (800) 934-5556 or visit